Iterum Therapeutics (ITRM) Stock Price

Iterum Therapeutics Price

NASDAQ·CLOSED
0.00
​
Market closed

Revenue at Iterum Therapeutics has contracted by 73.0% per year over the past 2 years to 37,000.00 USD. Iterum Therapeutics's net margin stands at -278,729.7%, down from -5,788.6% several years earlier.

Iterum Therapeutics stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Iterum Therapeutics business model & stock analysis

Iterum Therapeutics Plc is a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. The company is headquartered in Dublin, Dublin and currently employs 44 full-time employees. The company went IPO on 2018-05-25. The firm is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The firm is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. The company is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. The company has demonstrated potent in vitro activity against all genera of Enterobacteriacease, in anaerobes such as Bacteroides, Prevotella, Porphyromonas, Fusobacterium and Peptostreptococcus, gram-positive organisms including methicillin-susceptible staphylococci, Streptococcus pyogenes and Streptococcus pneumonia.

Frequently asked questions about Iterum Therapeutics

8 analysts currently rate the Iterum Therapeutics stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Iterum Therapeutics to generate revenue of 10.00 M USD and earnings per share of -0.65 USD.

Converted at the current exchange rate, the Iterum Therapeutics share trades at 0.00 EUR (0.00 USD).

The Iterum Therapeutics share (ITRM) is listed on 1 stock exchanges, including: NASDAQ (ITRM).

The expected revenue of Iterum Therapeutics is 10.00 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Iterum Therapeutics is -12.79 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Iterum Therapeutics is currently -0.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Iterum Therapeutics stock.

The price-to-sales ratio (P/S) of Iterum Therapeutics is currently 0.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Iterum Therapeutics stock.

The Eulerpool Quality Score for Iterum Therapeutics is 3/10.

The ISIN of Iterum Therapeutics is IE000TTOOBX0. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Iterum Therapeutics is A2JMZP. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Iterum Therapeutics is ITRM. The ticker symbol is used to trade Iterum Therapeutics shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website iterumtx.com
Country
Ireland
Currency
USD
Initial public offering
May 25, 2018
ISIN
IE000TTOOBX0
Cusip
G6333L101
Sedol
BF3W0Q3
Market capitalization
5,329.00 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2025
-0.00
P/Ee 2026
-0.00
P/Ee 2027
-0.00
P/Ee 2028
-0.00
P/Ee 2029
0.00
P/S
P/Se
0.00
EV/EBIT
0.14
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-59.76 %
Last updated Nov 3, 2026, 11:42 AM

Iterum Therapeutics Ticker

NASDAQ · ITRM

All fundamentals and in-depth analysis of Iterum Therapeutics

Our stock analysis for Iterum Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Iterum Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.